{"nctId":"NCT00289783","briefTitle":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","startDateStruct":{"date":"2006-02-22"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"count":4441,"armGroups":[{"label":"Menhibrix A Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","Biological: Pediarix","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]},{"label":"Menhibrix B Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","Biological: Pediarix","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]},{"label":"Menhibrix C Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","Biological: Pediarix","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]},{"label":"Menhibrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","Biological: Pediarix","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ActHIB","Biological: PedvaxHIB"]}],"interventions":[{"name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","otherNames":[]},{"name":"ActHIB","otherNames":[]},{"name":"PedvaxHIB","otherNames":[]},{"name":"Pediarix","otherNames":["Infanrix penta"]},{"name":"Prevnar","otherNames":[]},{"name":"M-M-R II","otherNames":[]},{"name":"Varivax","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol\n* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Born after 36 weeks gestation.\n* Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrollment.\n* Infants may have received a birth dose of Bacillus Calmette-Guérin (BCG) vaccine.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s). (Synagis® \\[palivizumab, MedImmune\\], Prevnar (Prevenar), rotavirus vaccine, and influenza vaccine are allowed.\n* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of hepatitis B vaccine.\n* History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, and/or poliovirus disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at time of enrollment.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n\nAdditional specific criteria for the US subjects in Cohort 1. In addition, for Cohorts 2 and 3, subjects should not be administered M-M-R II and Varivax if any of these criteria apply:\n\n* History of measles, mumps, rubella or varicella.\n* Previous vaccination against measles, mumps, rubella or varicella.\n* Hypersensitivity to any component of the vaccines, including gelatin or neomycin.\n* Patients receiving immunosuppressive therapy.\n* Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.\n* Individuals with primary and acquired immunodeficiency states.\n* Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.\n* Individuals with active tuberculosis.\n* Acute disease at time of booster vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"15 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.170","spread":null},{"groupId":"OG001","value":"11.424","spread":null},{"groupId":"OG002","value":"11.438","spread":null},{"groupId":"OG003","value":"11.021","spread":null},{"groupId":"OG004","value":"6.463","spread":null}]}]}]},{"type":"PRIMARY","title":"Neisseria Meningitidis Serogroup C (MenC) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers","description":"Titers were expressed as Geometric Mean Titers (GMTs)\n\nThis analysis occured on the cohort 1 : Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"910.0","spread":null},{"groupId":"OG001","value":"1118.0","spread":null},{"groupId":"OG002","value":"885.7","spread":null},{"groupId":"OG003","value":"967.6","spread":null},{"groupId":"OG004","value":"2.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Neisseria Meningitidis Serogroup Y (MenY) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers","description":"Titers are expressen as Geometric Mean Titers (GMTs)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178.9","spread":null},{"groupId":"OG001","value":"288.1","spread":null},{"groupId":"OG002","value":"249.6","spread":null},{"groupId":"OG003","value":"236.6","spread":null},{"groupId":"OG004","value":"2.2","spread":null}]}]}]},{"type":"PRIMARY","title":"hSBA-MenC Antibody Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2039.8","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.3","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"PRIMARY","title":"hSBA-MenY Antibody Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1389.5","spread":null},{"groupId":"OG001","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.1","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL)","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"175","spread":null},{"groupId":"OG002","value":"166","spread":null},{"groupId":"OG003","value":"499","spread":null},{"groupId":"OG004","value":"156","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 150 Milli-international Units Per Milli-liter (mIU/ML)","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody concentrations below 150 mIU/mL.\n\nCo-administration with MMR-II vaccine","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"815","spread":null},{"groupId":"OG001","value":"274","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-mumps Titer Equal to or Above 28 Estimated Dose 50 (ED50)","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-mumps antibody titers below 28 ED50\n\nCo-administration with MMR-II vaccine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"595","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 10 International Units Per Milli-litre (IU/mL)","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody concentrations below 4 IU/mL.\n\nCo-administration with MMR-II vaccine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"848","spread":null},{"groupId":"OG001","value":"284","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-varicella Titer Equal to or Above 1:5","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody titer below 1:5.\n\nCo-administration with Varivax vaccine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"722","spread":null},{"groupId":"OG001","value":"223","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-tetanus (Anti-T) and Anti-diphtheria Toxoid (Anti-D) Antibody Concentrations Equal to or Above 0.1 International Units Per Millilitre (IU/mL)","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D and Anti-T Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in international units per milliliter (IU/mL).\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above 10.0 Milli-international Units Per Millilitre (mIU/mL)","description":"Results are stratified by the presence or absence of a birth dose of hepatitis B vaccine.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBS Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in milli-International units per milliliter (mIU/mL)\n\nResults are stratified by the presence or absence of a birth dose of hepatitis B vaccine.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1963.2","spread":null},{"groupId":"OG001","value":"2187.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1672.7","spread":null},{"groupId":"OG001","value":"3593.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations Equal to or Above 5 ELISA Units Per Millilitre (EL.U/mL)","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243.8","spread":null},{"groupId":"OG001","value":"293.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"103.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-poliovirus Types 1, 2 and 3 Equal to or Above 8 Estimated Dose 50 (ED50)","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-poliovirus Types 1, 2 and 3 Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"591.8","spread":null},{"groupId":"OG001","value":"590.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"496.7","spread":null},{"groupId":"OG001","value":"452.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1367.7","spread":null},{"groupId":"OG001","value":"1239.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibodies to Neisseria Meningitidis Serogroup C and Y Polysaccharide Capsule (Anti-PSC and Anti-PSY) Concentrations Equal to or Above the Cut-off Values","description":"Anti-PSC and anti-PSY antibody cut-off values assessed were \\>=0.3 microgram per milliliter (µg/mL) and \\>=2.0 µg/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSC and Anti-PSY Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per milliliter (µg/mL)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations Equal to or Above the Cut-off Values","description":"Anti-PRP antibody cut-off values assessed were \\>=0.15 microgram per milliliter (µg/mL) and \\>=1.0 µg/mL.\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations Equal to or Above the Cut-off Values","description":"Anti-PRP antibody cut-off values assessed were \\>=0.15 microgram per milliliter (µg/mL) and \\>=1.0 µg/mL.\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL)\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.984","spread":null},{"groupId":"OG001","value":"24.050","spread":null},{"groupId":"OG002","value":"20.489","spread":null},{"groupId":"OG003","value":"23.165","spread":null},{"groupId":"OG004","value":"29.759","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL)\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.340","spread":null},{"groupId":"OG001","value":"4.123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132.965","spread":null},{"groupId":"OG001","value":"92.800","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Titers Equal to or Above the Cut-off Values","description":"hSBA-MenC/Y antibody cut-off values assessed were \\>=1:4 and \\>=1:8\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"133","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"133","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Titers Equal to or Above the Cut-off Values","description":"hSBA-MenC/Y antibody cut-off values assessed were \\>=1:4 and \\>=1:8.\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA-MenC and hSBA-MenY Antibody Titers","description":"Titres are expressed as Geometric Mean Titers (GMTs).\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3055.8","spread":null},{"groupId":"OG001","value":"3370.7","spread":null},{"groupId":"OG002","value":"3119.3","spread":null},{"groupId":"OG003","value":"3172.6","spread":null},{"groupId":"OG004","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"666.5","spread":null},{"groupId":"OG001","value":"916.7","spread":null},{"groupId":"OG002","value":"989.6","spread":null},{"groupId":"OG003","value":"837.2","spread":null},{"groupId":"OG004","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA-MenC and hSBA-MenY Antibody Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs)\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"504.7","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10132.9","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"446.5","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5775.8","spread":null},{"groupId":"OG001","value":"27.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSC and Anti-PSY Antibody Concentrations Equal to or Above the Cut-off Values","description":"Anti-PSC and anti-PSY antibody cut-off values assessed were \\>=0.3 microgram per milliliter (µg/mL) and \\>=2.0 µg/mL.\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSC and Anti-PSY Antibody Concentrations Equal to or Above the Cut-off Values","description":"Anti-PSC and anti-PSY antibody cut-off values assessed were \\>=0.3 µg/mL and \\>=2.0 µg/mL.\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSC and Anti-PSY Antibodies Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per milliliter (µg/mL).\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSC and Anti-PSY Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL).\n\nThe analysis was performed on the cohort 3 (Non-US Safety and Immunogenicity): Cohort 3 was to include the subjects enrolled at 1 center in Mexico. Only descriptive immunogenicity results were reported for this cohort. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.63","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.66","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations Equal to or Above the Cut-off Value","description":"Anti-PRP antibody cut-off values assessed were \\>=0.15 µg/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"518","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"162","spread":null},{"groupId":"OG003","value":"180","spread":null},{"groupId":"OG004","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL).\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.802","spread":null},{"groupId":"OG001","value":"6.086","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.615","spread":null},{"groupId":"OG001","value":"0.832","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Equal to or Above the Cut-off Values","description":"hSBA-MenC and hSBA-MenY antibody cut-off values assessed were \\>=1:4 and \\>=1:8.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"485","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"156","spread":null},{"groupId":"OG003","value":"167","spread":null},{"groupId":"OG004","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"485","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"156","spread":null},{"groupId":"OG003","value":"167","spread":null},{"groupId":"OG004","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"463","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"141","spread":null},{"groupId":"OG003","value":"165","spread":null},{"groupId":"OG004","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"461","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"140","spread":null},{"groupId":"OG003","value":"165","spread":null},{"groupId":"OG004","value":"156","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSC and Anti-PSY Antibody Concentrations Equal to or Above the Cut-off Values","description":"Anti-PSC and anti-PSY antibody cut-off values assessed were \\>=0.3 µg/mL and \\>=2.0 µg/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"313","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"325","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSC and Anti-PSY Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL).\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":null},{"groupId":"OG001","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.81","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.15","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.26","spread":null},{"groupId":"OG001","value":"0.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations Equal to or Above 0.15 Microgram Per Milliliter (µg/mL)","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in microgram per millilitre (µg/mL)\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.851","spread":null},{"groupId":"OG001","value":"20.200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.617","spread":null},{"groupId":"OG001","value":"0.759","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Concentrations Equal to or Above 1:4","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"309","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 200 Milli-international Units Per Millilitre (mIU/mL)","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody concentrations below 150 mIU/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"812","spread":null},{"groupId":"OG001","value":"273","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-measles Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in milli-international units per milliliter (mIU/mL).\n\nThe analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody concentrations below 150 mIU/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1990.0","spread":null},{"groupId":"OG001","value":"1989.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-mumps Titer Equal to or Above the Cut-off Values","description":"Anti-mumps antibody cut-off values assessed were \\>=28 estimated dose 50 (ED50) and \\>=51 ED50.\n\nThe analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-mumps antibody titers below 24 ED50.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"532","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"490","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-mumps Antibody Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs).\n\nThe analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-measles antibody titers below 24 ED50.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123.9","spread":null},{"groupId":"OG001","value":"114.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 4 International Units Per Millilitre (IU/mL)","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-rubella antibody concentrations below 4 IU/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"850","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-rubella Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) and are expressed in international units per milliliter (IU/mL).\n\nThe analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-rubella antibody concentrations below 4 IU/mL.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":null},{"groupId":"OG001","value":"74.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-varicella Titer Equal to or Above 1:40","description":"The analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-rubella antibody concentrations below 1:5\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"722","spread":null},{"groupId":"OG001","value":"223","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-varicella Antibody Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs)\n\nThe analysis was performed on initially seronegative subjects. Seronegative subjects are subjects with anti-varicella antibody titers below 1:5\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"407.1","spread":null},{"groupId":"OG001","value":"394.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-H1N1, Anti-H3N2 and Anti-influenza-B (Anti B) Antibody Titers Equal to or Above 1:40","description":"anti-H1N1, anti-H3N2 and anti-influenza-B (anti B) antibody were measured by hemagglutination inhibition assay (HIA), in subjects who received 2 doses of influenza vaccine within the same influenza season of which at least one dose is concomitant with the study vaccine. For the purposes of this study, concomitant administration of influenza vaccine was defined as administration within 28 days before to 7 days after administration of study vaccines.\n\nThis analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Fever Above 39.5 Degrees Celsius/103.1 Degrees Fahrenheit","description":"Fever is defined as temperature (rectal or axillary/tympanic) above 39.5 degrees Celsius (°C) or 103.1 degrees Fahrenheit (°F).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Fever Above 39.5 Degrees Celsius/103.1 Degrees Fahrenheit","description":"Fever is defined as temperature (rectal or axillary/tympanic) above 39.5 degrees Celsius (°C) or 103.1 degrees Fahrenheit (°F).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and General Symptoms","description":"Solicited local symptoms assessed were pain, redness and swelling. Solicited genral symptoms assessed were fever, irritability/fussiness, drowsiness and loss of appetite. Fever is defined as temperature (rectal or axillary/tympanic) equal to or above 38.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1849","spread":null},{"groupId":"OG001","value":"672","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1679","spread":null},{"groupId":"OG001","value":"596","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1454","spread":null},{"groupId":"OG001","value":"522","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2419","spread":null},{"groupId":"OG001","value":"819","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1152","spread":null},{"groupId":"OG001","value":"401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1455","spread":null},{"groupId":"OG001","value":"483","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1409","spread":null},{"groupId":"OG001","value":"495","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2052","spread":null},{"groupId":"OG001","value":"691","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"893","spread":null},{"groupId":"OG001","value":"281","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1091","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1110","spread":null},{"groupId":"OG001","value":"381","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1707","spread":null},{"groupId":"OG001","value":"568","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1864","spread":null},{"groupId":"OG001","value":"655","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1588","spread":null},{"groupId":"OG001","value":"552","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1260","spread":null},{"groupId":"OG001","value":"444","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2418","spread":null},{"groupId":"OG001","value":"804","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"688","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"803","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"609","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1434","spread":null},{"groupId":"OG001","value":"463","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2156","spread":null},{"groupId":"OG001","value":"782","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2074","spread":null},{"groupId":"OG001","value":"708","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1771","spread":null},{"groupId":"OG001","value":"600","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2740","spread":null},{"groupId":"OG001","value":"926","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1024","spread":null},{"groupId":"OG001","value":"375","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"921","spread":null},{"groupId":"OG001","value":"317","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"828","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1764","spread":null},{"groupId":"OG001","value":"609","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and General Symptoms","description":"Solicited local symptoms assessed were pain, redness, swelling and an increase in limb circumference. Solicited general symptoms assessed were fever, irritability/fussiness, drowsiness and lost of appetite. Fever is defined as temperature (rectal or axillary/tympanic) equal to or above 38.0°C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1319","spread":null},{"groupId":"OG001","value":"494","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1213","spread":null},{"groupId":"OG001","value":"463","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"936","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1489","spread":null},{"groupId":"OG001","value":"503","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1088","spread":null},{"groupId":"OG001","value":"381","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1482","spread":null},{"groupId":"OG001","value":"534","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"825","spread":null},{"groupId":"OG001","value":"287","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events (AEs)","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1820","spread":null},{"groupId":"OG001","value":"602","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events (AEs)","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1010","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s)","description":"Increased circumferential swelling defined as either swelling with a diameter of \\>50 mm or a \\>50 mm increase in the circumference of the mid-limb when compared to the baseline (pre-vaccination) measurement, or any diffuse swelling that interferes with or prevents everyday activities (for example, active playing, eating, sleeping).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1489","spread":null},{"groupId":"OG001","value":"503","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting General Symptoms Specific to Measles, Mumps, Rubella and Varicella Vaccination","description":"Symptoms assessed were fever, rash/exanthem, parotid/salivary gland swelling, and any suspected signs of meningism including febrile convulsions. Fever is defined as temperature (rectal or axillary/tympanic) equal to or above 38.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting New Onset of Chronic Illness(es) (NOCDs)","description":"NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting New Onset of Chronic Illness(es) (NOCDs)","description":"NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"470","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits","description":"Emergency room (ER) visits were not related to well-child care, vaccination, injury or common acute illness such as upper respiratory tract infections; otitis media, pharyngitis, gastroenteritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits.","description":"Physicians (MD) office visits were not related to well-child care, vaccination, injury or common acute illness such as upper respiratory tract infections; otitis media, pharyngitis, gastroenteritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1336","spread":null},{"groupId":"OG001","value":"433","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits","description":"Emergency room (ER) visits were not related to well-child care, vaccination, injury or common acute illness such as upper respiratory tract infections; otitis media, pharyngitis, gastroenteritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits","description":"Physicians (MD) office visits were not related to well-child care, vaccination, injury or common acute illness such as upper respiratory tract infections; otitis media, pharyngitis, gastroenteritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"668","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL).","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titer Equal to or Above 1:8.","description":"This analysis occurred on the cohort 1: Cohort 1 was to include subjects in the US on which all immunogenicity analyses were to be based. These subjects also contributed to the safety analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":126,"n":3136},"commonTop":["Irritability","Pain","Drowsiness","Redness","Loss of appetite"]}}}